ClinicalTrials.gg
RecruitingNCT06062888Updated Nov 18, 2026

FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial

A Phase 2/3 interventional study of Fresh Frozen Plasma (FFP) in Moderate to Severe Traumatic Brain Injury, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Northwestern University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
357
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 909 studies in Brain Injuries, Traumatic with a site in United States — 212 open to participants now, 250 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.

Planned enrollment
42nd of 650
357 · median 50
Started
2026
with 64 others
Phase 2/3
13 of 909
2 open now
Primary completion
2028-08
later than 190 of 249 live
Registered
753rd of 909
by date

Among the 909 studies in Brain Injuries, Traumatic with a site in United States, this one is the 42nd largest by planned enrollment of the 650 interventional ones that give a count, is one of 65 that started in 2026, is one of 13 in phase 2/3, reaches primary completion later than 190 of the 249 other live ones, and was the 753rd registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

212 of the 909 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:

207 more — sign in →

All 212 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Brain Injuries, Traumatic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about treatment with fresh frozen plasma (FFP) in individuals with moderate to severe traumatic brain injury. The two main question[s]it aims to answer are:

  • Is the FFP treatment safe?
  • Does the FFP treatment impact the 24-hour, 3-month and 6-month outcomes, intensive-care free days, mortality, and hospital brain and physical function at discharge. Patients with moderate to severe TBI will randomly receive either:

    • Standard of care treatment
    • Standard of care treatment + 2 units of FFP. Researchers will compare participants receiving standard of care treatment to those receiving experimental fresh frozen plasma (FFP) treatment to see if the FFP is safe and beneficial to participant outcomes.
Read the detailed description

The two units of fresh frozen plasma will consist of 400-500 ml. The 24-hour, 3-month and 6-month outcome measures include hemorrhagic progression of contusion (HPC) measured on 24-hour follow-up CT scan, the Disability Rating Score (DRS), 24-hour Glasgow Coma Scale (GCS) and the 3-month and 6-month Extended Glasgow Outcome Score (GOS-E).

A third sub aim of the trial is to establish peripheral blood biomarkers, and radiographic features on the initial cross- sectional imaging, that could identify the optimal target population and predict the response to treatment.

03

Conditions studied

  • Moderate to Severe Traumatic Brain Injury

Keywords

  • TBI
  • Traumatic Brain Injury
  • Fresh frozen plasma
  • FFP
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female between the ages of 18 and 65 years
  2. Moderate to severe TBI: GCS 3-12
  3. Cerebral trauma confirmed on the initial CT scan with radiographic findings consistent with Brain Injury Guidelines category 3 (BIG 3).
  4. The potential participant's wallet, when present, was examined and no power of attorney related to blood product administration was identified.

Exclusion criteria

Exclusion Criteria:

  1. Persons with a known history of adverse reaction to plasma products.
  2. Persons with a known history of congestive heart failure, renal failure, liver failure, or severe respiratory dysfunction requiring home use of supplemental oxygen.
  3. Persons who are currently incarcerated.
  4. Persons with inadequate venous access.
  5. Treatment cannot start within 1 hour of arrival at the hospital.
  6. The time of injury is unknown.
  7. Non-survivable injuries in the estimation of the attending trauma and/or neurosurgeon.
  8. Interfacility transfers
  9. Class 3 hemorrhagic shock
  10. Persons with known "do not resuscitate" orders prior to randomization
  11. Persons who refuse the administration of blood products
  12. Persons with a research "opt out" bracelet
  13. Persons who require FFP for any other indication (e.g., reversal of coagulopathy)
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
357 participants (estimated)

Study arms

  • No intervention
    Standard of Care

    Standard of Care Control Group

  • Experimental
    Standard of Care + FFP

    Standard of Care + Experimental Treatment

    Biological: Fresh Frozen Plasma (FFP)

Interventions

06

What researchers measure

Primary outcomes

  1. Extended Glasgow Outcome Scale (GOS-E)

    Scoring values range from 1 to 8 with higher scores representing a better outcome. 1 indicates death, 2 indicates a vegetative state, 3 or 4 indicates severe disability, 5 or 6 indicates moderate disability, and 7 or 8 indicates good recovery.

    Time frame: 3 months

Secondary outcomes

  1. Hemorrhagic progression of the contusion (HPC)

    We will quantify HPC as the change in volume of the largest contiguous brain lesion in mm. This will be measured through a comparison of the initial and the follow-up CT scan.

    Time frame: The first 24 hour post-injury

  2. Disability Rating Scale (DRS)

    This scale includes eight categories: A. Eye opening (0-5), B. Communication ability (0-4), C. Motor response (0-5), D. Feeding - cognitive ability only (0-3), E. Toileting - cognitive ability only (0-3), F. Grooming - cognitive ability only (0-3), G. Level of functioning - physical, mental, emotional or social function (0-5) and H. "Employability" - a full time worker, homemaker, or student (0-3). Higher scores in each category mean a worse outcome.

    Time frame: Discharge or day 7 of the hospital stay and 3 months post-injury

Other outcomes

  1. Disability Rating Scale (DRS)

    This scale includes eight categories: A. Eye opening (0-5), B. Communication ability (0-4), C. Motor response (0-5), D. Feeding - cognitive ability only (0-3), E. Toileting - cognitive ability only (0-3), F. Grooming - cognitive ability only (0-3), G. Level of functioning - physical, mental, emotional or social function (0-5) and H. "Employability" - a full time worker, homemaker, or student (0-3). Higher scores in each category mean a worse outcome.

    Time frame: 6 months post-injury

  2. Extended Glasgow Outcome Scale (GOS-E)

    Scoring values range from 1 to 8, with higher scores representing a better outcome. 1 indicates death, 2 indicates a vegetative state, 3 or 4 indicates severe disability, 5 or 6 indicates moderate disability, and 7 or 8 indicates good recovery.

    Time frame: 6 months post-injury

  3. Time to treatment

    Time to treatment measured in hours and minutes.

    Time frame: The first 24 hours post-injury

  4. Contusion volume

    Total contusion volume measured in mm3

    Time frame: The first 24 hours post-injury

  5. Non-contiguous contusions

    Count of non-contiguous contusions

    Time frame: The first 24 hours post-injury

  6. Glasgow Coma Scale (GCS)

    This scale uses three behavior categories to measure response with larger numbers and total score representing a better outcome. They are: Eye opening response (4-1), Best verbal response (5-1) and Best motor response (6-1). Of the total score 15=Best response, 8 or less = Comatose client and 3=Totally unresponsive.

    Time frame: The first 24 hours post-injury

  7. TBI severity sub-stratification using the Glasgow Coma Scale (GCS)

    his scale uses three behavior categories to measure response with larger numbers and total score representing a better outcome. They are: Eye opening response (4-1), Best verbal response (5-1) and Best motor response (6-1). Of the total score 15=Best response, 8 or less = Comatose client and 3=Totally unresponsive. (GCS 9-12) = moderate and (GCS 3-8)=severe

    Time frame: The first 24 hours post-injury

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Liggett MR, Lashley S, Gill NP, Scholtens DM, Dawood ZS, Alam HB. Plasma therapy for traumatic brain injury: Rationale for a prospective randomized trial. Transfusion. 2024 Jul;64(7):1362-1371. doi: 10.1111/trf.17928. Epub 2024 Jun 28. No abstract available. PubMed 38940059 ↗
  • Joseph B, Obaid O, Dultz L, Black G, Campbell M, Berndtson AE, Costantini T, Kerwin A, Skarupa D, Burruss S, Delgado L, Gomez M, Mederos DR, Winfield R, Cullinane D; AAST BIG Multi-institutional Study Group. Validating the Brain Injury Guidelines: Results of an American Association for the Surgery of Trauma prospective multi-institutional trial. J Trauma Acute Care Surg. 2022 Aug 1;93(2):157-165. doi: 10.1097/TA.0000000000003554. Epub 2022 Mar 28. PubMed 35343931 ↗
  • Jin G, Liggett MR, Ho JW, Dawood ZS, Chtraklin K, Diaz D, Alam HB. Plasma treatment is associated with decreased brain lesion and resuscitation requirements after traumatic brain injury in a swine model of prolonged damage-control resuscitation. J Trauma Acute Care Surg. 2024 Dec 1;97(6):954-960. doi: 10.1097/TA.0000000000004457. Epub 2024 Oct 15. PubMed 39733294 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Aug 2028, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2023
First posted
Oct 2, 2023
StartActual
Feb 1, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Jun 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06062888
Responsible party
Hasan Alam (Chair, Department of Surgery, Northwestern University) — Principal investigator
First posted
Oct 2, 2023
Start date
Feb 1, 2026
Primary completion
Aug 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Hasan Alam, MD
Contact
Hasan.Alam@nm.org
312-926-4962
Nicole Meredyth, MD
Contact
nicole.meredyth@nm.org
312-694-4867
Hasan Alam, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human plasma

Start the discussion